A Single-arm Phase II Trial of Palliative "QUAD SHOT" Radiotherapy Combined With Pembrolizumab in Patients With Recurrent Head & Neck Cancer
Latest Information Update: 21 Feb 2025
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms QUADSHOT
- 13 Feb 2025 Planned End Date changed from 1 Oct 2025 to 1 Oct 2026.
- 13 Feb 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Jan 2026.
- 11 Dec 2024 Planned primary completion date changed from 1 Oct 2024 to 1 Jan 2025.